Psoriatic arthritis: genetic susceptibility and pharmacogenetics.
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. The etiology of PsA is unknown; however, there is mounting evidence for a strong genetic contribution to PsA. A few disease-related genes have already been identified in PsA. Cytokines associated with PsA appear to be the most promising targets for pharmacogenetics. Blockade of TNF-alpha and IL-12/23 is associated with a marked clinical response to PsA and/or psoriasis, implying a pivotal role of these cytokines in the pathogenesis of these two disease entities. To date, only the -308 variant of the TNF-alpha promoter gene has been shown to be important in predicting response to TNF-alpha blockade in inflammatory arthritis.
Rahman
Proton
P
Memorial University, Discipline of Rheumatology, School of Pharmacy and Faculty of Medicine, Health Science Centre, 300 Prince Philip Drive, St John's, NL, A1B 3V6, Canada. prahman@mun.ca
O'Rielly
Darren D
DD
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000235:genetics*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics; D013256:Steroids / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D013256:Steroids